Rodriguez-Rivera Frances P, Levi Samuel M
Discovery Chemistry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Pfizer Worldwide Research and Development, Pfizer, Inc., 1 Portland Street, Cambridge, Massachusetts 02139, United States.
ACS Cent Sci. 2021 Jul 28;7(7):1117-1125. doi: 10.1021/acscentsci.1c00389. Epub 2021 Jun 16.
Diverging from traditional target inhibition, proteasomal protein degradation approaches have emerged as novel therapeutic modalities that embody distinct pharmacological profiles and can access previously undrugged targets. Small molecule degraders have the potential to catalytically destroy target proteins at substoichiometric concentrations, thus lowering administered doses and extending pharmacological effects. With this mechanistic premise, research efforts have advanced the development of small molecule degraders that benefit from stable and increased affinity ternary complexes. However, a holistic framework that evaluates different degradation modes from a catalytic perspective, including focusing on kinetically favored degradation mechanisms, is lacking. In this Outlook, we introduce the concept of an induced cooperativity spectrum as a unifying framework to mechanistically understand catalytic degradation profiles. This framework is bolstered by key examples of published molecular degraders extending from molecular glues to bivalent degraders. Critically, we discuss remaining challenges and future opportunities in drug discovery to rationally design and phenotypically screen for efficient degraders.
与传统的靶点抑制不同,蛋白酶体蛋白降解方法已成为一种新型治疗方式,具有独特的药理学特征,能够作用于以前难以成药的靶点。小分子降解剂有潜力在亚化学计量浓度下催化破坏靶蛋白,从而降低给药剂量并延长药理作用。基于这一机制前提,研究工作推动了小分子降解剂的开发,这些降解剂受益于稳定且增强的亲和力三元复合物。然而,目前缺乏一个从催化角度评估不同降解模式的整体框架,包括关注动力学上有利的降解机制。在本展望文章中,我们引入诱导协同光谱的概念,作为一个统一框架,以从机制上理解催化降解谱。已发表的分子降解剂的关键例子,从分子胶到二价降解剂,都支持了这一框架。至关重要的是,我们讨论了药物发现中在合理设计和表型筛选高效降解剂方面仍然存在的挑战和未来机遇。